The Journal of the Association of Physicians of Tamil Nadu
Issue 2
A Case of Myelodysplastic Syndrome: Rare Hypercellular Bone Marrow Feature
Open Access
Volume 1,
Issue 2
,
June 2022
,
Pages 29-33
The journal is published as a quarterly issue.
AUTHORS
Dr. K. Siva Kumar1,
B. Lakshmi2,
Dr. R. Abarna Lakshmi3
1 –
|
Department of General Medicine, Karunya Sugalaya Diabetes Care and Research Centre Pvt. Ltd, |
2 –
|
Department of Diabetology, Karunya Sugalaya Diabetes Care and Research Centre Pvt. Ltd, |
3 –
|
Department of Clinical Research, Karunya Sugalaya Diabetes Care and Research Centre Pvt. Ltd, |
HISTORY
Available Online:
June 2022
ABSTRACT
Background:Myelodysplastic syndrome (MDS) is a broad array of hematological conditions defined by peripheral cytopenia, dysplastic hematopoietic progenitors, normal or hypercellular or hypocellular bone marrow, and a high risk of transition to acute myeloid leukemia.Case Report:During a regular follow-up, a 59- year-old female patient presented to our hospital with complaints of fatigue and a severe headache. A complete blood count was performed, and it was reported that the patient had pancytopenia, which was persistent. Iron, folic acid, and vitamin B12 levels in the blood were extremely low, while LDH and ferritin levels were extremely high. A biopsy revealed that the patient had hypercellular bone marrow with dyspoiesis of the cells, excess blasts in immunohistology, and a 5-q deletion in karyotyping. The patient was then diagnosed with myelodysplastic syndrome with rare hypercellular characteristics.Conclusion:Blood transfusions and immunomodulating medications like azacytidine or decitabine are the treatments. Regular monitoring of hematological symptoms is needed to prevent the progression of the disease.
KEYWORDS
refractory pancytopenia,
hypercellular bone marrow,
dyspoiesis,
5q deletion,
immunomodulating agents.
COPYRIGHT
© 2022 Dr. Vijay Viswanathan, published by Association of Physicians of India-Tamilnadu State Chapter